A Small Peptide with Therapeutic Potential for Inflammatory Acne Vulgaris

A designed peptide named LZ1 with 15 amino acid residues containing strong antimicrobial activity against bacteria pathogens of acne vulgaris including Propionibacterium acnes, Staphylococcus epidermidis and S. aureus. Especially, it exerted strong anti-P. acnes ability. The minimal inhibitory concentration against three strains of P. acnes was only 0.6 µg/ml, which is 4 times lower than that of clindamycin. In experimental mice skin colonization model, LZ1 significantly reduced the number of P. acnes colonized on the ear, P. acnes-induced ear swelling, and inflammatory cell infiltration. It ameliorated inflammation induced by P. acnes by inhibiting the secretion of inflammatory factors including tumor necrosis factor-α (TNF-α) and interleukin (IL)-1β. LZ1 showed little cytotoxicity on human keratinocyte and hemolytic activity on human blood red cells. Furthermore, LZ1 was very stable in human plasma. Combined with its potential bactericidal and anti-inflammatory properties, simple structure and high stability, LZ1 might be an ideal candidate for the treatment of acne.

[1]  Soonsil Hyun,et al.  Reduction of Helical Content by Insertion of a Disulfide Bond Leads to an Antimicrobial Peptide with Decreased Hemolytic Activity , 2013, ChemMedChem.

[2]  Christopher M Yip,et al.  Roles of Hydrophobicity and Charge Distribution of Cationic Antimicrobial Peptides in Peptide-Membrane Interactions* , 2012, The Journal of Biological Chemistry.

[3]  Hailong Yang,et al.  Cathelicidin-BF, a Snake Cathelicidin-Derived Antimicrobial Peptide, Could Be an Excellent Therapeutic Agent for Acne Vulgaris , 2011, PloS one.

[4]  J. Leyden,et al.  In-vivo Effectiveness of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel on Antibiotic-sensitive and Resistant Propionibacterium acnes. , 2011, The Journal of clinical and aesthetic dermatology.

[5]  I. Kurokawa,et al.  Involvement of Propionibacterium acnes in the augmentation of lipogenesis in hamster sebaceous glands in vivo and in vitro. , 2009, The Journal of investigative dermatology.

[6]  J. Raingeaud,et al.  Production of Superoxide Anions by Keratinocytes Initiates P. acnes-Induced Inflammation of the Skin , 2009, PLoS pathogens.

[7]  L. Eichenfield,et al.  A Novel Gel Formulation of 0.25% Tretinoin and 1.2% Clindamycin Phosphate: Efficacy in Acne Vulgaris Patients Aged 12 to 18 Years , 2009, Pediatric dermatology.

[8]  C. Zouboulis,et al.  Sebocytes express functional cathelicidin antimicrobial peptides and can act to kill propionibacterium acnes. , 2008, The Journal of investigative dermatology.

[9]  Chongxing Zhang,et al.  The first antimicrobial peptide from sea amphibian. , 2008, Molecular immunology.

[10]  Jianxu Li,et al.  Anti-infection Peptidomics of Amphibian Skin *S , 2007, Molecular & Cellular Proteomics.

[11]  W. Cunliffe,et al.  Temporal changes in sebum excretion and propionibacterial colonization in preadolescent children with and without acne , 2007, The British journal of dermatology.

[12]  C. Nord,et al.  Antibiotic resistance in Propionibacterium acnes. Microbiological and clinical aspects. , 2006, Anaerobe.

[13]  C. Zouboulis,et al.  Propionibacterium acnes and lipopolysaccharide induce the expression of antimicrobial peptides and proinflammatory cytokines/chemokines in human sebocytes. , 2006, Microbes and infection.

[14]  A. Schmidtchen,et al.  Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids. , 2006, The Journal of antimicrobial chemotherapy.

[15]  M. Schaller,et al.  Induction of a chemoattractive proinflammatory cytokine response after stimulation of keratinocytes with Propionibacterium acnes and coproporphyrin III , 2005, The British journal of dermatology.

[16]  N. Asthana,et al.  Dissection of Antibacterial and Toxic Activity of Melittin , 2004, Journal of Biological Chemistry.

[17]  H. Williams,et al.  Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial , 2004, The Lancet.

[18]  Gillian M. Graham,et al.  Proinflammatory cytokine production by human keratinocytes stimulated with Propionibacterium acnes and P. acnes GroEL , 2004, The British journal of dermatology.

[19]  J. Swanson.  Antibiotic resistance of Propionibacterium acnes in acne vulgaris. , 2003, Dermatology nursing.

[20]  W. Cunliffe,et al.  Inflammatory events are involved in acne lesion initiation. , 2003, The Journal of investigative dermatology.

[21]  H. Gollnick,et al.  Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. , 2003, Journal of the American Academy of Dermatology.

[22]  Kyung-Soo Hahm,et al.  Selective cytotoxicity following Arg‐to‐Lys substitution in tritrpticin adopting a unique amphipathic turn structure , 2003, FEBS letters.

[23]  Michael R. Yeaman,et al.  Mechanisms of Antimicrobial Peptide Action and Resistance , 2003, Pharmacological Reviews.

[24]  K. Hahm,et al.  A Leu-Lys-rich antimicrobial peptide: activity and mechanism. , 2003, Biochimica et biophysica acta.

[25]  J. Leyden,et al.  Propionibacterium acnes Resistance: A Worldwide Problem , 2003, Dermatology.

[26]  S. Akira,et al.  Activation of Toll-Like Receptor 2 in Acne Triggers Inflammatory Cytokine Responses1 , 2002, The Journal of Immunology.

[27]  J. Svendsen,et al.  Antimicrobial activity of short arginine‐ and tryptophan‐rich peptides , 2002, Journal of peptide science : an official publication of the European Peptide Society.

[28]  K. T. Holland,et al.  A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. , 2002, Clinical therapeutics.

[29]  V. Eijsink,et al.  Mutational analysis of the role of tryptophan residues in an antimicrobial peptide. , 2002, Biochemistry.

[30]  Wen-Hui Lee,et al.  Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima , 2002, Peptides.

[31]  W. Cunliffe,et al.  Human beta defensin-1 and -2 expression in human pilosebaceous units: upregulation in acne vulgaris lesions. , 2001, The Journal of investigative dermatology.

[32]  C. Burkhart,et al.  Acne: a review of immunologic and microbiologic factors , 1999, Postgraduate medical journal.

[33]  B D Sykes,et al.  Dissociation of Antimicrobial and Hemolytic Activities in Cyclic Peptide Diastereomers by Systematic Alterations in Amphipathicity* , 1999, The Journal of Biological Chemistry.

[34]  J. Johansson,et al.  Apolipoprotein A-I Binds and Inhibits the Human Antibacterial/Cytotoxic Peptide LL-37* , 1998, The Journal of Biological Chemistry.

[35]  S. White,et al.  The preference of tryptophan for membrane interfaces. , 1998, Biochemistry.

[36]  H. Gollnick,et al.  Topical Drug Treatment in Acne , 1998, Dermatology.

[37]  J. Leyden,et al.  Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: implications for chronic inflammatory acne , 1995, Infection and immunity.

[38]  J. Cove,et al.  Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure , 1989, The British journal of dermatology.

[39]  P. Norris,et al.  (1) Juvenile spring eruption of the ears: a re‐examination , 1989 .

[40]  J. Leyden,et al.  Characterization of serum-independent polymorphonuclear leukocyte chemotactic factors produced byPropionibacterium acnes , 1980, Inflammation.

[41]  K. T. Holland,et al.  Purification and partial characterization of an acid phosphatase (EC 3.1.3.2) produced by Propionibacterium acnes. , 1980, Journal of general microbiology.

[42]  I. Crawford,et al.  Laboratory induction and clinical occurrence of combined clindamycin and erythromycin resistance in Corynebacterium acnes. , 1979, The Journal of investigative dermatology.

[43]  U. Hoeffler.  Enzymatic and hemolytic properties of Propionibacterium acnes and related bacteria , 1977, Journal of clinical microbiology.

[44]  G. Pulverer,et al.  Antimicrobial Susceptibility of Propionibacterium acnes and Related Microbial Species , 1976, Antimicrobial Agents and Chemotherapy.

[45]  S. M. Puhvel,et al.  The production of hyaluronidase (hyaluronate lyase) by Corynebacterium acnes. , 1972, The Journal of investigative dermatology.

[46]  J. Q. Rosso,et al.  Antimicrobial Property of Lauric Acid Against Propionibacterium Acnes: Its Therapeutic Potential for Inflammatory Acne Vulgaris , 2011 .

[47]  C. Zouboulis,et al.  Clindamycin phosphate/tretinoin gel formulation in the treatment of acne vulgaris. , 2008, Expert opinion on pharmacotherapy.

[48]  G. A. Castro,et al.  Novel vesicular and particulate drug delivery systems for topical treatment of acne. , 2008, Expert opinion on drug delivery.

[49]  J. Leyden,et al.  Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. , 2007, Cutis.

[50]  M. Rendon,et al.  The use of fillers and botulinum toxin type A in combination with superficial glycolic acid (alpha-hydroxy acid) peels: optimizing injection therapy with the skin-smoothing properties of peels. , 2007, Cutis (New York, N.Y.).

[51]  V. Nizet.  Antimicrobial peptide resistance mechanisms of human bacterial pathogens. , 2006, Current issues in molecular biology.

[52]  R. Böni,et al.  Treatment of Gram-Negative Folliculitis in Patients with Acne , 2003, American journal of clinical dermatology.

[53]  H. Vogel,et al.  Tryptophan-rich antimicrobial peptides: comparative properties and membrane interactions. , 2002, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[54]  M Toscano,et al.  [Acne vulgaris]. , 1992, Canadian family physician Medecin de famille canadien.